Literature DB >> 2171163

Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages.

D Niederwieser1, M Herold, W Woloszczuk, W Aulitzky, B Meister, H Tilg, G Gastl, R Bowden, C Huber.   

Abstract

Serum levels of interferon-gamma and the IFN-dependent marker molecules neopterin and beta 2-microglobulin were assessed in BMT recipients. Concentrations of the latter two markers were corrected for creatinine levels in order to eliminate the impact of alteration of kidney function. Serum levels were assessed daily using commercially available radioimmunoassays. Twelve patients were studied during the early phase of allogeneic bone marrow transplantation and eleven additional patients during complications of BMT. Results indicated that both the conditioning regimen for BMT as well as major clinical complications such as infection and acute graft-versus-host disease strongly influence the endogenous patterns of the lymphokine and its secondary messages. During allogeneic BMT IFN-gamma and neopterin levels exhibited a biphasic pattern with a first peak during conditioning with high-dose cyclophosphamide and a second still higher peak at the time of hemopoietic regeneration. beta-2-microglobulin ratios increased during conditioning and remained elevated throughout observation. Serious infections of bacterial and viral origin as well as GvHD were accompanied by elevated levels of all three serum parameters studied. The kinetics of enhanced endogenous production, however, differed between infectious complications and GvHD. Increasing concentrations were observed during infections subsequent to clinical manifestation, whereas they preceded disease manifestation in GvHD.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171163     DOI: 10.1097/00007890-199010000-00019

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  22 in total

1.  Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma.

Authors:  H Tilg; C van Montfrans; A van den Ende; A Kaser; S J H van Deventer; S Schreiber; M Gregor; O Ludwiczek; P Rutgeerts; C Gasche; J C Koningsberger; L Abreu; I Kuhn; M Cohard; A LeBeaut; P Grint; G Weiss
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

2.  Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity.

Authors:  Bradley W Blaser; Noah R Schwind; Seth Karol; Dennis Chang; Samuel Shin; Sameek Roychowdhury; Brian Becknell; Amy K Ferketich; Donna F Kusewitt; Bruce R Blazar; Michael A Caligiuri
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

3.  An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation.

Authors:  Wannee Asavaroengchai; Hui Wang; Shumei Wang; Lan Wang; Roderick Bronson; Megan Sykes; Yong-Guang Yang
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

4.  Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function.

Authors:  M B Baker; R L Riley; E R Podack; R B Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

5.  Kinetics of interferon-gamma secretion and its regulatory factors in the early phase of acute graft-versus-host disease.

Authors:  H Z Hu; G L Li; Y K Lim; S H Chan; E H Yap
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

6.  Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants.

Authors:  Archana Thakur; Carly Sorenson; Oxana Norkina; Dana Schalk; Voravit Ratanatharathorn; Lawrence G Lum
Journal:  Transfusion       Date:  2011-07-11       Impact factor: 3.157

7.  CD8 serum levels in acute graft-versus-host disease diagnosis.

Authors:  P Bavaro; T Bonfini; G Di Girolamo; A Angelini; P Di Bartolomeo; F Angrilli; G Papalinetti; P Olioso; G Torlontano
Journal:  J Clin Immunol       Date:  1994-07       Impact factor: 8.317

8.  KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.

Authors:  Jeanette E Boudreau; Fabio Giglio; Ted A Gooley; Philip A Stevenson; Jean-Benoît Le Luduec; Brian C Shaffer; Raja Rajalingam; Lihua Hou; Carolyn Katovich Hurley; Harriet Noreen; Elaine F Reed; Neng Yu; Cynthia Vierra-Green; Michael Haagenson; Mari Malkki; Effie W Petersdorf; Stephen Spellman; Katharine C Hsu
Journal:  J Clin Oncol       Date:  2017-05-18       Impact factor: 44.544

9.  Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.

Authors:  Y G Yang; B R Dey; J J Sergio; D A Pearson; M Sykes
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

10.  Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia.

Authors:  H Schönbohn; M Schuler; K Kolbe; C Peschel; C Huber; W Bemb; W E Aulitzky
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.